The Point of Diminishing Returns: An Examination of Expanding Vancouver's Insite

Urban Studies

Volumn 49, Issue 16, 2012, Pages 3531-3544

  Andresen, Martin A ^a   Jozaghi, Ehsan ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST-BENEFIT ANALYSIS; DRUG USER; GOVERNANCE APPROACH; HEALTH CARE; PUBLIC HEALTH; RISK ASSESSMENT;

BRITISH COLUMBIA; CANADA; VANCOUVER;

EID: 84870416815     PISSN: 00420980     EISSN: 1360063X     Source Type: Journal    
DOI: 10.1177/0042098012443865     Document Type: Article

References (53)

1. Albert T.,Williams G.,Legowski B.,Remis R.The economic burden of HIV/AIDS in Canada. Ottawa, ON: Canadian Policy Research Networks; 1998:.
2. Andresen M. A.,Boyd N. T.A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility.International Journal of Drug Policy. 2010;21:70-76.
3. Barnes T.,Sutton T.Situating the new economy: contingencies of regeneration and dislocation in Vancouver's inner city.Urban Studies. 2009;46:1247-1269.
4. Bayoumi A. M.,Zaric G. S.The cost-effectiveness of Vancouver's supervised injection facility.Canadian Medical Association Journal. 2008;179:1143-1151.
5. STD/AIDS: 2005 annual report. Vancouver, BC: BC Centre for Disease Control; 2005:.
6. HIV and AIDS: annual supplement report 2009. Vancouver, BC: BC Centre for Disease Control; 2009:.
7. Bravo M. J.,Royuela L.,Fuente L.,de la Brugal M. T., et al.Use of supervised injection facilities and injection risk behaviours among young drug injectors.Addiction. 2009;104:614-619.
8. Buxton J.Vancouver drug use epidemiology: site report for the Canadian community epidemiology network on drug use. Ottawa, ON: Canadian Centre on Substance Abuse; 2008:.
9. Chen R. Y.,Accortt N. A.,Westfall A. O.,Mugavero M. J., et al.Distribution of health care expenditures for HIV-infected patients.Clinical Infectious Diseases. 2006;42:1003-1010.
10. CTV News (2008) Experts table findings on drug-injection site. Vancouver, Canada (http://www.ctv.ca; accessed 12 April 2008).
11. DeBeck K.,Kerr T.,Bird L.,Zhang R., et al.Injection drug use cessation and use of North America's first medically supervised safer injecting facility.Drug and Alcohol Dependence. 2011;113:172-176.
12. Des Jarlais D. C.,Arasteh K.,Hagan H.Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics.Canadian Medical Association Journal. 2008;179:1105-1106.
13. Des Jarlais D. C.,Friedman S. R.,Choopanya K.,Vanichsenis S., et al.International epidemiology among injecting drug users.AIDS. 1992;6:1053-1068.
14. Des Jarlais D. C.,Marmor M.,Paone D.,Titus S., et al.HIV incidence among injecting drug users in New York City syringe-exchange programmes.Lancet. 1996;348:987-991.
15. Fast D.,Shoveller J.,Shannon K.,Kerr T.Safety and danger in downtown Vancouver: understandings of place among young people entrenched in an urban drug scene.Health & Place. 2010;16:51-60.
16. Harvard S. S.,Hill W. D.,Buxton J. A.Harm reduction product distribution in British Columbia.Canadian Journal of Public Health. 2008;99:446-450.
17. Health Canada (2008) Expert panel report on supervised injection site released. Health Canada press release, Ottawa, Canada (http://www.hc-sc.gc.ca/ahcasc/media/nr-cp/2008/200857e.html; accessed 23 April 2008).
18. Holtgrave D. R.,Pinkerton S. D.Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1997;16:55-61.
19. Holtgrave D. R.,Pinkerton S. D.,Jones T. S.,Lurie P., et al.Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998;18:S133-S138.
20. Jacobs P.,Calder P.,Taylor M.,Houston S., et al.Cost effectiveness of Streetworks' needle exchange program of Edmonton.Canadian Journal of Public Health. 1999;90:168-171.
21. Kaplan E. H.Economic analysis of needle exchange.AIDS. 1995;9:1113-1119.
22. Kaplan E. H.,O'Keefe E.Let the needles do the talking! Evaluating the New Haven needle exchange.Interfaces. 1993;23:7-26.
23. Kerr T.,Tyndall M.,Li K.,Montaner J. S.,Wood E.Potential use of safer injecting facilities among injection drug users in Vancouver's downtown eastside.Canadian Medical Association Journal. 2005a;169:759-763.
24. Kerr T.,Tyndall M.,Li K.,Montaner J. S.,Wood E.Safer injection facility use and syringe sharing in injection drug users.Lancet. 2005b;366:316-318.
25. Krüsi A.,Small W.,Wood E.,Kerr T.An integrated supervised injecting program within a care facility for HIV-positive individuals: a qualitative evaluation.AIDS Care. 2009;21:638-644.
26. Laufer F. N.Cost-effectiveness of syringe exchanges as an HIV prevention strategy.Journal of Acquired Immune Deficiency Syndromes. 2001;28:273-278.
27. Lert F.,Kazatchkine M. D.Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview.International Journal of Drug Policy. 2007;18:255-261.
28. Ley D.,Smith H.Relations between deprivation and immigrant groups in large Canadian cities.Urban Studies. 2000;37:37-62.
29. Lurie P.,Drucker E.An opportunity lost: HIV infections associated with a lack of a national needle-exchange programme in the USA.Lancet. 1997;349:604-608.
30. Lurie P.,Gorsky R.,Jones T. S.,Shomphe L.An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998;18:S126-S132.
31. Lurie P.,Reingold A. L.,Bowser B.,Chen D., et alThe public health impact of needle exchange programs in the United States and abroad: summary, conclusions and recommendations. Berkeley, CA: School of Public Health, University of California; 1993:.
32. Marshall B. D. L.,Milloy M.-J.,Wood E.,Montaner J. S. G., et al.Reduction in overdose mortality after opening of North America's first medically supervised safer injecting facility: a retrospective population-based study.Lancet. 2011;377:1429-1437.
33. Marshall B. D. L.,Wood E.,Zhang R.,Tyndall M. W., et al.Condom use among injection drug users accessing a supervised injection facility.Sexually Transmitted Infections. 2009;85:121-126.
34. McClean M. E.Vancouver drug use epidemiology-2001: Vancouver and BC site report for the Canadian community epidemiology network on drug use. Vancouver, BC: Richmond Health Board; 2002:.
35. Ogilvie M.Safe injection site would work in T.O., study suggests: preliminary version of long-awaited report says city would benefit from up to three clinics.Toronto Star. 2011;:A1.
36. Petrar S.,Kerr T.,Tyndall M. W.,Zhang R., et al.Injection drug users' perceptions regarding use of a medically supervised safer injection facility.Addictive Behaviors. 2007;32:1088-1093.
37. Pinkerton S. D.Is Vancouver Canada's supervised injection facility cost-saving?.Addiction. 2010;105:1429-1436.
38. Pinkerton S. D.How many HIV infections are prevented by Vancouver Canada's supervised injection facility?.International Journal of Drug Policy. 2011;22:179-183.
39. Pinkerton S. D.,Holtgrave D. R.Handbook of Economic Evaluation of HIV Programs. Holtgrave D. R., ed. New York: Plenum; 1998:33-43.
40. Reddon H.,Wood E.,Tyndall M.,Lai C., et al.Use of North America's first medically supervised safer injecting facility among HIV-positive injection drug users.AIDS Education and Prevention. 2011;23:412-422.
41. Remis R. S.,Leclerc P.,Routledge R.,Taylor C., et alConsortium to characterize injection drug users in Canada (Montreal, Toronto, and Vancouver). Bureau of HI/AIDS and STD, Laboratory Centre for Disease Control Health Canada, Ottawa, ON; 1998:.
42. Séguin R.,Peritz I.Quebec opens door to setting up safe-injection sites.Globe and Mail. 2011;:.
43. Siegel J. E.,Weinstein M. C.,Fineberg H. V.Bleach programs for preventing AIDS among IV drug users: modelling the impact of HIV prevalence.American Journal of Public Health. 1991;81:1273-1279.
44. Small D.An appeal to humanity: legal victory in favour of North America's only supervised injection facility, Insite.Harm Reduction Journal. 2010;7:23.
45. Tyndall M. W.,Currie S.,Spittal P.,Li K., et al.Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic.AIDS. 2003;17:887-893.
46. Tyndall M. W.,Wood E.,Zhang R.,Lai C., et al.HIV seroprevalence along participants of a supervised injection facility in Vancouver, Canada.Harm Reduction Journal. 2006;3:36-40.
47. Vancouver Coastal Health (2007) Insite-supervised injection site. Health Services, Vancouver Coastal Health, Vancouver, Canada (http://www.vch.ca/sis/; accessed 1 December 2007).
48. Vlahov D.,Junge B.The role of needle exchange programs in HIV prevention.Public Health Reports. 1998;113:75-80.
49. Watters J.,Estilo M.,Clark G.,Lorvick J.Syringe and needle exchange as HIV/AIDS prevention for injection drug users.Journal of the American Medical Association. 1994;271:115-120.
50. Wood E.,Kerr T.,Small W.,Li K., et al.Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users.Canadian Medical Association Journal. 2004;171:731-734.
51. Wood E.,Tyndall M. W.,Lai C.,Montaner J. S. G., et al.Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime.Substance Abuse Treatment, Prevention, and Policy. 2006;1:.
52. Wood E.,Tyndall M. W.,Spittal P. M.,Li K., et al.Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?.Canadian Medical Association Journal. 2001;165:405-410.
53. Wood E.,Tyndall M. W.,Zhang R.,Stoltz J., et al.Attendance of supervised injecting facilities and use of detoxification services.New England Journal of Medicine. 2006;354:2512-2514.